Indirect treatment comparisons of the gene therapy etranacogene dezaparvovec (CSL222) vs. extended half-life Factor IX therapies for severe or moderately severe hemophilia B
R. Klamroth, A. Bonner, S. Yan, P. Monahan, K. Szafranski, M. Herepath, X. Zhang, K. Gomez
{"title":"Indirect treatment comparisons of the gene therapy etranacogene dezaparvovec (CSL222) vs. extended half-life Factor IX therapies for severe or moderately severe hemophilia B","authors":"R. Klamroth, A. Bonner, S. Yan, P. Monahan, K. Szafranski, M. Herepath, X. Zhang, K. Gomez","doi":"10.1055/s-0042-1760567","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":217767,"journal":{"name":"GTH Congress 2023 – 67th Annual Meeting of the Society of Thrombosis and Haemostasis Research – The patient as a benchmark","volume":"14 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"GTH Congress 2023 – 67th Annual Meeting of the Society of Thrombosis and Haemostasis Research – The patient as a benchmark","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1055/s-0042-1760567","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
